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ABSTRACT
Objectives: To investigate the clinical features, disposition, and effect of pregnancy complicated with Takayasu arteritis 
(P-TA) on maternal and fetal outcomes.
Material and methods: The clinical data (diagnosis and treatment, peri-pregnancy monitoring, and pregnancy outcomes) 
of patients with P-TA treated in our hospital between September 2007 and April 2016 were analyzed retrospectively.
Results: Among the 13 P-TA cases, seven were diagnosed before pregnancy, and six were diagnosed during pregnancy; 
six cases were diagnosed as the generalized type, and seven cases were diagnosed as the cephalic-brachial type; six cases 
were in the stable stage, and seven cases were in the active stage. All the cases in the active stage underwent glucocorticoid 
therapy. Four cases developed complications, including cardiac dysfunction combined with preeclampsia in two cases, 
preeclampsia in one case, and stroke in one case. Eleven patients successfully delivered (nine cases of full-term delivery and 
two cases of premature delivery); one patient had late miscarriage; one patient had missed abortion. All the parturients 
survived and delivered 11 neonates (nine full-term neonates and two premature neonates) and one low-birth-weight 
neonate; no neonatal asphyxia or death occurred.
Conclusions: Patients with P-TA can have better maternal and child outcomes through timely diagnosis and treatment, 
dynamic monitoring, or timely pregnancy termination.
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INTRODUCTION
Takayasu arteritis (TA) refers to a chronic progressive 
non-specific inflammatory disease in the aorta and its main 
branches, and the lesions are more commonly seen in the 
aortic arch and its branches, followed by the descending aor-
ta, abdominal aorta, and renal artery; the involved vessels 
can present full-thickness arteritis, which leads to vascular 
wall thickening, stenosis, and fibrosis [1–3]. Its etiology is 
not clear yet and may be related to infection and other 
factors caused by an immune damage [4]. This disease oc-
curs more commonly in young women [5], and the male to 
female sex ratio is 1:4; approximately 90% of the patients are 
younger than 30 years, and those older than 40 years have 
a rare onset of this disease. The prevalence of TA in foreign 
countries is approximately 2.6 in every 1 million individuals 
[4, 5]. Because this disease is mainly seen in women at the 
childbearing age; the patients have an extremely strong 
pregnancy request [6, 7]; and even some patients are dia-
gnosed with this disease for the first time, our attention was 
focused on whether patients with TA can conceive and on 
how to manage the mother and child to achieve good out-
comes. Previously, the understanding of pregnancy related 
to TA mainly comes from domestic and foreign case reports 
or small-number case reports, in which most cases are in 
the stable stage; the number of cases in the active stage is 
low; and cases delivering in the active stage are rare. TA may 
occur with peri-pregnancy hypertension, heart failure, cere-
brovascular accidents, fetal growth restriction, or even fetal 
death [5–10]; thus, we focused on whether patients with TA 
can conceive and on how to manage the mother and child 
to achieve good outcomes [8]. There has been no systematic 
and effective report regarding peri-pregnancy monitoring or 
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specific treatment measures targeting patients with TA [11]; 
therefore, to determine convenient and effective peri-pre-
gnancy treatment measures and monitoring means, we 
summarized the data of 13 pregnancy complicated with 
Takayasu arteritis (P-TA) cases treated in our hospital, inc-
luding seven cases in the active stage of TA, and provided 
specific and feasible advice for their pregnancy monitoring 
and relevant management to achieve good maternal and 
fetal outcomes.
OBJECTIVES
This study provides a new method of achieving good 
maternal and fetal outcomes among patients with P-TA and 
consequently makes pregnancy in such patients possible. 
The clinical data of these 13 P-TA cases between September 
2007 and April 2016 are reported as follows.
MATERIAL AND METHODS
General information
Thirteen patients with P-TA, aged 25–35 years, who were 
admitted to the Department of Obstetrics and Gynecology, 
Beijing Anzhen Hospital between September 2007 and April 
2016 were enrolled; their mean age was 30.31 ± 3.22 years; 
and their mean age at diagnosis was 27.85 ± 2.85 years. Ten 
patients were primiparas, and three were multiparas; seven 
patients were diagnosed before pregnancy (Cases 1, 3, 4, 6, 
8, 9, and 13). Case 1 underwent descending aorta-abdominal 
aorta arterial bypass before pregnancy. Case 9 underwent 
ascending aorta-left carotid artery bypass. Six patients were 
diagnosed during pregnancy (Cases 2, 5, 7, and 10–12). The 
patients’ general information is shown in Table 1. This study 
was conducted in accordance with the declaration of Helsin-
ki. This study was conducted with approval from the Ethics 
Committee of Capital Medical University. Written informed 
consent was obtained from all participants.
Diagnostic criteria [1]
All the patients were diagnosed using the classification 
criteria issued by the American Rheumatology Association 
in 1990: 1) age at onset: ≤ 40 years: symptoms or signs 
appearing before the age of 40 years; 2) intermittent limb 
dyskinesia: one or more limbs, especially the upper limb(s), 
experience gradually increased fatigue and muscle discom- 
fort when doing activities; 3) brachial artery pulsation 
weakening: unilateral or bilateral brachial artery pulsation 
weakening; 4) blood pressure (BP) difference of > 10 mm Hg: 
systolic pressure difference between the bilateral upper 
limbs of > 10 mm Hg; 5) subclavian artery or aortic murmur: 
lateral or bilateral subclavian artery or abdominal aorta mur-
mur; 6) angiographic abnormalities: the first aortic branch 
or the proximal aorta of the upper/lower limbs exhibits ste-
noses or occlusions, often as focal or segmental lesions, not 
due to atherosclerosis, fibroid dysplasia, or similar causes.
Any case which meets three out of the six above-men-
tioned criteria can be diagnosed as TA, and the sensitivity 
and specificity of the diagnostic criteria were 90.5% and 
97.8%, respectively.
Clinical classification [1]
According to the lesion sites, all the cases were divided 
into four types:
•	 Cephalic-brachial type (aortic arch syndrome): the ca-
rotid and vertebral arteries experience stenosis and 
occlusion, which can cause varying degrees of cerebral 
ischemia; further, the BP in the lateral or bilateral upper 
limbs was reduced or cannot be detected.
•	 Thoracic-abdominal aortic type: the lesion is located 
in the descending aorta and abdominal aorta, causing 
lower limb weakness, intermittent claudication, hyper-
tension, aortic valve insufficiency, or heart failure.
•	 Generalized type: the patient has a combination of the 
two abovementioned types, involving multiple lesions; 
most patients have severe lesions.
•	 Pulmonary artery type: the lesions are combined and 
located in the pulmonary artery, and pulmonary hyper-
tension may occur. Approximately 25% of patients with 
pulmonary artery type have pulmonary hypertension [12].
Indices for determining the TA stages [13]
1) Increased erythrocyte sedimentation rate (ESR) and 
C-reactive protein (CRP) level in the active stage and nor-
mal values in the stable stage; 2) systemic symptoms, such 
as fever or myalgia; 3) the involved blood vessels develop 
ischemia and inflammation, such as intermittent limb fa-
tigue, arterial pulse weakening or disappearing, vascular 
murmur, vascular pain, upper/lower limb BP asymmetry; 
4) typical TA angiographic findings. Any patient with two or 
more initial or aggravated symptoms can be determined as 
being in the active stage.
RESULTS
Relationship between glucocorticoid 
administration and blood CRP level reduction
Among the 13 cases, seven were in the active stage (Cases 
2–5, 7, 11, and 12); these cases had an increased blood CRP 
level and underwent glucocorticoid therapy. Cases 2 and 
7 presented with heart failure on admission; consequently, 
their cardiac function was managed, and timely pregnancy 
termination was initiated. Thus, intravenous hydrocortisone 
treatment was provided before surgery. On Day 1, their blo-
od CRP levels decreased by 45.2% and 53.6%, respectively. 
Cases 3–5, 11, and 12 were orally administered with predni-
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sone (0.75 mg/pre-pregnancy body weight (kg)/day), and 
the reduction amplitudes of their blood CRP levels on Days 
3–5 were all greater than 20%. Cases 3, 4, and 12 underwent 
pregnancy termination owing to their full-term status. Ca-
ses 5 and 11 exhibited blood CRP level reduction-to-nor-
mal 2 weeks after medication administration, which was 
maintained thereafter (oral administration of prednisone 
2.5 mg/time/day). The pregnancy of Case 5 was maintained 
until > 35 gestational weeks, and that of Case 11 was main-
tained until full term and then terminated (Fig. 1).
All the patients in the active stage were intravenously 
administered with hydrocortisone for 3 days during the perio-
perative period, which was changed to oral administration of 
prednisone later (while maintaining the preoperative dosage) 
and added with cyclophosphamide 1 week after surgery.
Maternal and fetal outcomes
Among the seven cases in the active stage, two had 
two complications (Cases 2 and 7), and two had only one 
complication (Cases 5 and 11). Finally, four patients delivered 
full-term infants; two patients delivered premature infants 
(> 35 and > 36 gestational weeks, respectively); and one 
patient had late abortion. Among all the 13 patients, 11 pa-
tients underwent cesarean section in their third pregnancy 
trimester, including nine full-term deliveries and two prema-
ture deliveries (> 35 and > 36 gestational weeks, respective-
ly), and all the infants survived. Among the 11 infants, only 
one had a low birth weight (2270 g); all the infants exhibited 
an Apgar score of 10-10-10, and no neonatal suffocation 
or death occurred. The maternal and fetal outcomes are 
shown in Table 2.
DISCUSSION
TA is a chronic inflammatory vasculitis with an unknown 
cause, which mainly affects the greater vessels and aorta, 
as well as its main branches; TA leads to thickening, steno-
sis, and fibrosis of the blood vessels [1–3]. Its pathogene-
sis remains unclear, and existing studies have shown that 
multiple factors, such as immunity, genetics, infection, or 
sex hormones, may be involved in TA [4]. Studies have also 
shown that histocompatibility antigens have a significant 
correlation with TA [14]; a large number of epidemiologi-
cal studies have shown that TA dominates in women, with 
a male to female sex ratio of 1:4. The levels of estradiol and 
progesterone in patients in either the active or stable stage 
are higher than those in healthy women, indicating that 
the elevated levels of sex hormones may be an important 
factor that can affect the pathogenesis of TA. In addition, TA 
may be related to chronic antigen stimuli in Mycobacterium 
tuberculosis, which can then induce non-immune-specific 
responses [4]; this may be the reason why this disease is 
more common in Southeast Asia, Central and South Ameri-
ca, or Africa [5]. The incidence of TA is low, and more patients 
are aged < 30 years, i.e., women at the childbearing age; 
such patients have an extremely strong pregnancy requ-
est [6, 7], and even some patients are diagnosed with this 
disease for the first time. As such, we focused on whether 
patients with TA can conceive and on how to manage the 
mother and child to achieve good outcomes [8]. According 
to previous case reports, TA may occur with hypertensi-
ve disorders, heart failure, cerebrovascular accidents, fetal 
growth restriction, or even fetal death during pregnancy 
[5–10]. Previously, the understanding of pregnancy related 
to TA mainly comes from domestic and foreign case reports 
or small-number case reports, in which most cases are in 
the stable stage; the number of cases in the active stage is 
low; and cases delivering in the active stage are even rare. 
There has been no systematic and effective report regarding 
peri-pregnancy monitoring or specific treatment measures 
targeting patients with TA [11]; we used convenient and ef-
fective peri-pregnancy treatment and monitoring measures 
and achieved satisfactory maternal and fetal outcomes.
The histological change in TA involves full-layer arterial 
inflammation or severe vascular stenosis/obstruction in 
the diseased vessels [2, 3], and the aorta is the main vessel 
involved during its pathophysiologic process; thus, invasion 
of the pulmonary artery is possible [2], which may even form 
aneurysms in rare cases [4, 5]. The pathophysiological chan-
ges in TA include ischemia in the distal end of lesions with 
BP increases in the proximal end. This disease often recurs, 
and the interior arterial wall may have a granulomatous in-
flammatory response, together with significant endometrial 
hyperplasia, fibrosis, and segmental involvement [2]. The 
indices of determining the disease stages include: 1) CRP 
level and ESR: important indices of disease stages. The CRP 
level and ESR increase faster in the active stage and can re-
turn to normal when the disease becomes stable; however, 
the ESR will also increase during pregnancy. Thus, only the 
Figure 1. Changes of serum CRP levels after administration of 
prednisone
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CRP level can be monitored during pregnancy; meanwhile, 
the effect of other factors, such as trauma or infection, on 
the CRP level should also be excluded. 2) Some patients 
may exhibit systemic symptoms, such as fever or myalgia. 
3) The involved blood vessels may develop ischemia and 
inflammation, such as intermittent fatigue, arterial pulse 
weakening or disappearing, vascular murmur, vascular pain, 
or upper limb or lower limb BP asymmetry. All the patients 
treated in our hospital experienced upper limb arterial pul-
se weakening or disappearing. 4) Patients exhibit typical 
angiographic TA findings, which directly manifest as chan-
ges in the involved vascular lumen, vascular diameter, wall 
conditions, and length and extent of the involved vessels; 
however, the thickness changes in the involved vessel wall 
cannot be shown. 
Color Doppler ultrasonography is a useful noninvasive 
means for assessing vasculitis responses [4] and can explore 
stenoses or occlusions in the aorta and its main branches 
(carotid artery, subclavian artery, or renal artery). Any pa-
tients with two or more initial or aggravated criteria can be 
determined as being in the active stage. Taking the effect of 
contrast agents and radiation on fetuses into account, an-
giography is not recommended during pregnancy. The ESR 
also increases during pregnancy; thus, it cannot be used as 
an effective monitoring indicator, making the CRP level and 
vascular ultrasound more effective and convenient inspec-
tion means during pregnancy. However, as the gestational 
weeks progress, the use of abdominal vascular ultrasound 
becomes limited, and related skill requirements and diffi-
culties toward the operators also increase; furthermore, the 
CRP level is not a TA-specific indicator and can be affected 
by infection, trauma, or other factors. Hence, the means 
of TA monitoring during pregnancy are extremely limited.
Pregnancy and TA affect each other. However, most 
scholars believe that pregnancy is not related to the deve-
lopment of TA [5, 15]; conversely, certain authors proposed 
that the abovementioned conclusions are based on the 
data reported [16], which still lack large-sample investiga-
tions. Owing to the increase in blood volume, BP can fur-
ther increase during pregnancy, thus causing preeclampsia, 
heart failure, cerebrovascular accident, or even death; the 
placental blood flow will also be affected, causing limited 
fetal growth or even fetal death [5–7]. At present, most 
scholars believe that patients with pre-pregnancy TA in the 
stable stage will have a better prognosis [6, 8, 9]. Conversely, 
some scholars also believe that there is no significance in 
the risk of maternal and fetal complications; however, the 
incidence of such complications is higher in these patients 
than in normal populations. However, this conclusion still 
needs further accumulation of relevant cases owing to the 
small case number reported [7]. Peking Union Medical Col-
lege Hospital (China) once reported seven cases of TA, six of 
which had their pre-pregnancy diseases in the stable stage; 
their pregnancies were all terminated in the late trimester 
with stable postpartum conditions. One case underwent 
pregnancy termination in the early trimester, as she was in 
the active stage, and a cerebrovascular accident occurred, 
thus exhibiting a poor prognosis. Comarmond et al. [17] 
retrospectively reviewed 240 pregnancies in 96 patients 
over 40 years in France and believed that controlling disease 
conditions before or during pregnancy has an important 
effect on improving parents’ outcomes. Among the 13 pa-
tients with P-TA treated in our hospital, six patients were 
in the stable stage, and seven patients were in the active 
stage; four patients out of the seven active stage patients 
developed complications during their pregnancy (57.14%). 
The seven patients were administered with glucocorticoids 
on time, and their CRP level satisfactorily decreased; the CRP 
level decreased to normal within 5 days in two patients and 
within 2 weeks in the other two patients (pregnancy was 
maintained until 35 and 37 gestational weeks, respectively, 
and was terminated thereafter). Among the seven active 
stage patients, four delivered in full term; two delivered 
prematurely (35 and 36 gestational weeks, respectively); 
and one had late abortion. All the mothers exhibited stable 
postpartum conditions and were continuously administered 
with glucocorticoids postoperatively; all of them survived 
without puerperal infections. Among the six infants, only 
one had a low birth weight (2270 g); no neonatal asphyxia or 
death occurred. Among the six stable pregnancies, five were 
maintained until 37 weeks, and one underwent complete 
curettage of the uterine cavity because of missed abortion in 
early pregnancy; all the patients were alive, and no neonatal 
asphyxia or death occurred. The abovementioned TA data 
in our hospital also reflect the features of TA (i.e., cases in 
the active stage had severe disease conditions); however, 
because the number of cases is limited, further case accu-
mulation is needed for related statistical analyses.
Most women with TA are at the childbearing age; thus, 
they normally have a strong desire to conceive; conside-
ring the abovementioned conditions, we believe that the 
disease state of such patients before pregnancy should be 
assessed, and those with stable disease conditions and good 
organ functions should be considered during pregnancy. 
However, they also need to be closely monitored [6]. TA-
-induced hypertension can lead to cerebrovascular diseases 
and serious complications, such as cerebral hemorrhage or 
cerebral infarction [18]; hence, treatment against active TA 
is essential. TA drug treatment can include glucocorticoids, 
immunosuppressive agents, (cyclophosphamide or me-
thotrexate), biological agents (anti-tumor necrosis factor 
agents), or anticoagulant drugs [6], among which hormonal 
drugs are the most important drugs against active TA I [6, 
19]. Because immunosuppressive agents and biological 
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agents may cause fetal malformations, they are not recom-
mended during pregnancy [6]. When CRP level monitoring 
in patients with P-TA reveals higher values than normal, the 
disease condition should be considered in the active stage 
after ruling out infection, trauma, or other factors, which 
would require adequate glucocorticoids. The diagnosis 
and treatment of all the active cases in our hospital were 
combined with the suggestions from the Department of 
Rheumatology Immunization: oral administration of pred-
nisone [0.75–1 mg/pre-pregnancy body weight (kg)/day] 
and monitoring of blood CRP level; if the CRP level can be 
decreased by more than 20% within 2 weeks, the disease 
control can be considered satisfactory. Consequently, the 
total dosage of prednisone can be gradually reduced by 
5–10% once; when the dosage of prednisone is reduced 
to 5–10 mg/day, such a dosage needs to be maintained on 
a long-term basis. Oral administration of prednisone can be 
withdrawn perioperatively, and intravenous administration 
of hydrocortisone can be switched (200 mg/day for a total 
of 3 days), followed by oral administration of prednisone 
(while maintaining the preoperative amount) and gradu-
al reduction every 2 weeks when the disease condition 
becomes stable; however, the reduction rate should be 
paid attention to. The active cases in our hospital achieved 
satisfactory blood CRP level decreases after 3–5 days of oral 
administration of prednisone; however, their drug reduction 
rate still adhered to 5–10% every 2 weeks to avoid a rebound 
due to a too rapid dosage reduction. Cases 2 and 7 already 
had heart failure on admission; therefore, their pregnan-
cies need to be terminated as soon as possible. Therefore, 
they were intravenously administered with hydrocortiso-
ne, and their CRP level decreased significantly (45.2% and 
53.6%, respectively). However, owing to the small number 
of cases, we still need to accumulate such cases further for 
observation. The risk of glucocorticoids toward mothers is 
that the body will be in the immunosuppressed state; thus, 
pregnant women are prone to infection and consequently 
to gestational diabetes (when combined with insulin resi-
stance increase) [9, 20], osteoporosis, pathological fractures, 
hypokalemia, gastrointestinal bleeding, intraocular pressure 
increase, or other adverse reactions. Glucocorticoids also 
need to be administered together with appropriate sup-
plementation of vitamin D, Ca2+, or K+, as well as electro-
lyte level, gastrointestinal reaction, or intraocular pressure 
monitoring. Meanwhile, glucocorticoids also have certain 
risks toward fetuses and even newborns, which can cause 
fetal growth restriction, stillbirth, neonatal adrenal insuf-
ficiency, or other adverse reactions; hence, fetal growth 
and intrauterine conditions should be closely monitored 
during medication administration, and newborns need to 
be observed to assess for possible adrenal insufficiency. As 
for anticoagulant drugs, aspirin 75–100 mg/day can be orally 
administered [19] and changed to subcutaneous injection 
of low molecular weight heparin 1 week before termina-
ting pregnancy. However, aspirin should be avoided after 
32 weeks of pregnancy because it can increase the risk of 
premature closure of the neonatal arterial catheter and 
neonatal pulmonary hypertension [20], and the mothers 
administered with this drug should be monitored via fetal 
echocardiography. In addition, TA can cause fetal growth 
restriction or even intrauterine fetal death; fetal growth 
should then be monitored during pregnancy, together with 
regular reviewing of fetal ultrasound results and fetal heart 
rate monitoring. Further, pregnancy should be timely termi-
nated on the basis of the patients’ specific circumstances.
Ishikawa and Maetani [21] divided P-TA into four stages 
and considered kidney diseases, secondary hypertension, 
aortic regurgitation, and aneurysm as important factors 
that will affect maternal outcomes: Stage I: free of the above 
complications; Stage IIa: with one mild complication; Sta-
ge IIb: with one serious complication; Stage III: with more 
than one complication; aortic regurgitation cases are all 
divided into Stage III. Vaginal delivery may be considered 
in patients classified under Stages I and IIa. However, BP 
increase in the second stage of labor can lead to cerebro-
vascular accidents; thus, it needs to be shortened. Patients 
classified under Stages IIb and III should be recommended 
to undergo cesarean section to terminate pregnancy [10]. 
When the fetus and placenta are delivered, the placental 
blood circulation is terminated, and a large volume of blo-
od then reflux and cause great load to the blood vascular 
system, which can consequently cause cardiovascular and 
cerebrovascular accidents [18]. BP should be closely moni-
tored during cesarean sections and anesthesia induction to 
avoid severe BP fluctuations. Currently, epidural anesthesia 
is more advocated owing to its lesser effect on the hemo-
dynamics [5, 22], and narcotic drugs can be administered in 
small doses to avoid considerable declines in BP; the brain 
function can be more easily monitored if the patients can be 
kept in an awake state, which can also avoid dramatic BP 
changes stimulated by extubation under general anesthesia 
[18, 22]. The 13 pregnancies in our hospital were terminated 
via surgery; 11 cases were in Stage IIb or above; 10 cases 
were induced with continuous epidural anesthesia; two 
cases with a more stable stage were induced with spinal 
anesthesia; and one case that underwent complete curet-
tage of the uterine cavity was induced with non-intubated 
general anesthesia. All the cases were anesthetized and 
underwent surgery smoothly, and the perioperative periods 
were uneventful.
Intraoperative intrauterine injection or intravenous 
application of oxytocin is applicable; it should be used to 
minimize its effect on the BP [10]. Patients with TA who 
undergo hormonal therapy may have increased risks of 
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postpartum infection [10], and the cases in our hospital 
were administered with postoperative antibiotics to prevent 
infection; no puerperal infection occurred in our study. Post-
partum patients are in the hypercoagulable state; therefore, 
they should be administered with anticoagulant drugs as 
early as possible, especially when the obstetric factors are 
stable, to avoid thrombosis. Postpartum blood circulation 
increases; the amount of liquid intake should then be paid 
attention to and controlled to avoid increasing the cardiac 
load and the incidence of pulmonary edema or cardiova-
scular and cerebrovascular accidents [5, 10]. Postpartum 
breast-feeding is not suitable, and appropriate rest should 
be ensured in these patients.
In summary, treatment against P-TA requires close co-
operation among the Departments of Obstetrics, Rheuma-
tology, Vascular, Cardiology, and Anesthesiology. Sharma 
et al. [23] once analyzed the outcomes of 24 pregnancies 
in 12 patients with P-TA within 20 years, including 17 live 
neonates (five neonatal growth restrictions and four pre-
term deliveries), five cases of intrauterine fetal death, and 
two cases of abortion. In this study, we studied 13 P-TA 
cases; seven active stage cases were administered with 
glucocorticoids during pregnancy; achieved significant ef-
fects, satisfactory decrease in the CRP level, and stabilized 
condition; and finally delivered four full-term neonates and 
two preterm neonates (> 35 and > 36 gestational weeks). 
There was one case of late abortion. The 13 P-TA cases inc-
luded 11 cases of mid- and late pregnancy deliveries (nine 
full-term cases and two premature cases), one case of late 
abortion, and one case of missed abortion; all the mothers 
survived. Eleven neonates survived (nine full-term neonates 
and two premature neonates), including one low-birth-we-
ight neonate. No neonatal asphyxia or death occurred; thus, 
a satisfactory clinical treatment outcome was obtained. This 
study provides important clinical data as well as a simple 
and feasible method for pregnancy monitoring, specific 
treatment measures, and maternal and fetal outcomes, so 
that patients with P-TA can have better maternal and fetal 
outcomes. However, the number of the clinical cases admit-
ted to our hospital is limited, and because the incidence of 
the disease is low, we still need to accumulate relevant cases 
in the future for further analyses to obtain more clinical data 
to provide more effective help for such patients. Therefore, 
timely diagnosis and close monitoring against TA, timely 
and adequate glucocorticoid administration against active 
TA cases, and monitoring of the CRP level as well as the ma-
ternal and fetal status to stabilize the disease, together with 
terminating pregnancy at the appropriate time, can yield 
good maternal and fetal outcomes.
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